Dr. Bhuyan serves on the boards of both Planned Parenthood Federation of America and Planned Parenthood Global. Her areas of ...

Wilding says that the presence of GLP-1 receptors in the brain is thought to be one of the key reasons why GLP-1 drugs can impact hunger, fullness and reward, as they allow these drugs to ...

Originally developed for type 2 diabetes, GLP-1 RAs have gained significant traction globally for obesity treatment. With 32% of Australians classified as obese in 2022 and the cost of obesity ...

Serena Williams weight loss explained: How tennis star lost over 30 pounds after birth of second daughter originally appeared ...

They compared patients prescribed GLP-1-RAs or SGLT2 inhibitors with 68,400 patients prescribed DPP-4 inhibitors, which previous studies suggest do not increase ARD risk.

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are no longer considered to officially be in shortage.

Between 168 patients in the GLP-1 agonist groups and 169 control patients, the mean difference in post-cessation weight gain was -2.59 kg (95% CI -3.70 t0 -1.48, P <0.00001).

An observational study published in JAMA Oncology looks at GLP-1 receptor agonists and cancer risk in adults with obesity. Prof Paul Pharoah, Professor of Cancer Epidemiology, Cedars-Sinai Medical ...

The analysis found that obesity-related cancer occurred in 150 of 3,178 surgery patients (5.76 cases per 1,000 person-years) and in 148 of 3,178 patients taking GLP-1s (5.64 cases per 1,000 person ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl peptidase-4 inhibitors, according to findings scheduled for presentation at ...